期刊文献+

^11C-[2-甲氧基]-左旋千金藤啶碱的制备及生物学评价 被引量:1

Synthesis of n C-M-1-SPD and its biodistribution in rats
原文传递
导出
摘要 目的探讨合成^11C-[2-甲氧基]-左旋千金藤啶碱(^11C M—l—SPD)的方法及其在大鼠体内的生物学分布。方法使用”C-三氟甲基磺酰甲烷(CH3-triflate)进行^11C标记M—l—SPD,采用“反应瓶”法制备^11C—M-l-SPD。SD大鼠25只,均为雄性,使用随机数字法将其分为5组,经尾静脉注入^11C—M—z—SPD0.2ml(22.2MBq),分别于5、15、30、60和90min后断头处死,取出肺、心、肝、脾、胃、肠、肾、肌肉、脑等组织器官。于上述时间点取出脑额叶、顶叶、颞叶、枕叶、小脑、海马、纹状体、丘脑、脑干,测质量。用γ计数仪测定各组织放射性计数,计算湿组织%ID/g。采用SPSS15.0软件进行方差分析。结果^11C—M—z—SPD放化合成时间约为15rain,时间校正后放化产率为16%~34%;^11C.M—Z—SPD注射液为无色,pH值约为6.5,放化纯大于95%^11C—M—z+SPD在体内吸收迅速,分布广泛,以肝、肾、心、脑、肺分布最多。静脉注入”C—M—Z—SPD5min后在各组织内放射性分布达到高峰,5min后各组织呈明显下降趋势,给药后60min,各脏器内放射性明显下降。^11C—M—z—SPD主要经肝、肾代谢,肝、肾组织在注药后5min放射性分布分别为(1.484±0.350)%ID/g和(1.323±0.153)%ID/g,90min分别为(0.478±0.059)%ID/g和(0.394±0.165)%ID/g。在胃、脾、肠、肌肉等组织放射性分布较少。各脑区内放射性分布5min达到高峰,各脑区放射性分布差异无统计学意义(F:0.054、0.690、0.333、0.487和0.686,P均〉0.05)。结论使用^11C模块自动化制备^11C—M.f—SPD简便快速,有望用于l-SPD的活体PET显像。 Objective To explore the synthesis method of ^11C-[ 2-O-CH3 ] -l-stepholidine( H C-M-1- SPD) and evaluate its biodistribution in rats. Methods H C-CH3-triflate was bubbled into the reactor of an automated remotely controlled radiosynthesizer module, which contained reaction materials in a V-tube. Twenty-five SD rats were randomly divided into 5 groups. Different organs (lung, heart, liver, spleen, stom- ach, intestine, kidney, muscle and brain) were excised at different time points (5, 15, 30, 60 and 90 rain) post-injection of H C-M-I-SPD (0.2 ml, 22.2 MBq). Then the counts per minute of each organ were measured, and the % ID/g was calculated. Biodistribution in different regions of the brain ( frontal lobe, apical lobe, temporal lobe, occipital lobe, cerebellum, hippocampus, striatum, thalamencephalon and brain stem) was further evaluated. Analysis of variance was used for data analysis with SPSS 15.0. Results The synthesis time of ^11C_M_l_SPD was 15 min. The overall radiochemical yield was 16%-34%. The product was colorless in a pH value of 6.5, and the radiochemical purity was more than 95%. Five min post-injection, the biodistribution of 11C-M-I-SPD reached high levels in the liver, kidney, heart, brain and lung, and then dropped quickly. Levels decreased clearly in most organs at 60 min after administration. The liver and kidney were the main excretory organs. The biodistribution of HC-M-I-SPD in liver and kidney was (1. 484±0.350) % ID/g and (1. 323 ± 0. 153 ) % ID/g at 5 min after administration and went down to (0. 478± 0. 039 ) % ID/g and (0. 394 ±0. 165 ) % ID/g at 90 min, respectively. Lower radioactivity was found in the stomach, spleen, intestine and muscle. The uptake of 11C-M-/-SPD in the brain reached a peak at 5 min after injection, and there was no significant differences in the brain regions ( F = 0. 054, 0. 690, 0. 333, 0. 487, 0.686, all P 〉0.05). Conclusion The automatic synthesis of I xC-M-l-SPD is simple and fast, which provides the feasibility of its usage in PET imaging in vivo.
出处 《中华核医学与分子影像杂志》 CSCD 北大核心 2012年第3期210-213,共4页 Chinese Journal of Nuclear Medicine and Molecular Imaging
基金 卫生部核医学重点实验室开放课题(WK006001)中国科学院药物研究所金国章院士赠送药物左旋千金藤啶碱,并在课题研究中给予指导和支持
关键词 左旋千金藤啶碱 碳放射性同位素 同位素标记 药代动力学 大鼠 L-SPD Carbon radioisotopes Isotope labeling Pharmacokinetics Rats
  • 相关文献

参考文献9

  • 1金国章.中药延胡索研究中的新发现[M]上海:上海科学技术出版社,2001157-174.
  • 2Constantinescu CC,Coleman RA,Pan ML. Striatal and extrastriatal microPET imaging of D2/D3 dopamine receptors in rat brain with [18F]fallypride and [18F]desmethoxfallypride[J].Synapse,2011.778-787.doi:10.1002/syn.20904.
  • 3Ojeda-Flores R,Ortega-López N,(A)vila-Rodríguez MA. Cardiac metabolism and perfusion evaluation in a rat model using 18F-FDG,1-11Cacetate,13NH3 and micro-positron emission tomography (microPET)[J].Archivos De Cardiologia De Mexico,2010.215-228.
  • 4Bing M,Philip SS,James E. Sensitivity of [11C]N-methylpyrrolidinyl benzilate ([11C]NMPYB) to endogenous acetylcholine:PET imaging vs tissue sampling methods[J].Nuclear Medicine and Biology,2004.393-397.
  • 5沈德莉;陈丽娟;谭云山.左旋千金藤啶碱对大鼠的慢性毒性和致突变试验[J]中国药理学与毒理学杂志,2000(5):397.
  • 6Zhang ZD,Zhou CM,Jin GZ. Pharmacokinetics and autoradiography of [3H] or [14C] stepholidine[J].Zhongguo Yaoli Xuebao,1990.289-292.
  • 7万赢,刘振国.多巴胺受体激动剂在帕金森病早期治疗中的作用研究进展[J].中华神经科杂志,2010,43(5):364-366. 被引量:2
  • 8Yanovsky Y,Li S,Klyuch BP. L-Dopa activates histaminergic neurons[J].The Journal of Physiology,2011.1349-1366.doi:10.1113/jphysiol.2010.203257.
  • 9蒋雨平,丁正同,王坚,周松美,金国章,沈丽丽.左旋千金藤啶碱治疗帕金森病[J].中国临床神经科学,2001,9(4):424-425. 被引量:1

二级参考文献25

  • 1李如奎 陈丽娟 等.左旋千金藤啶碱与溴隐亭合并治疗帕金森病[J].神经病学与神经康复学杂志,1996,3:15-17.
  • 2Zhang ZX,Roman GC,Hong Z,et al.Parkinson' s disease in China:prevalence in Beijing,Xian,and Shanghai.Lancet,2005,365:595-597.
  • 3Junghanns S,Fuhrmann JT,Simonis G,et al.Valvular heart disease in Parkinson' s disease patients treated with dopamine agonists:a reader-blinded monocenter echocardiography study.Mov Disord,2007,22:234-238.
  • 4Simonis G,Fuhrmann JT,Strasser RH.Meta-analysis of heart valve abnormalities in Parkinson' s disease patients treated with dopamine agonists.Mov Disord,2007,22:1936-1942.
  • 5Baker WL,Silver D,White CM,et al.Dopamine agonists in the treatment of early Parkinson' s disease:a meta-analysis.Parkinsonism Relat Disord,2009,15:287-294.
  • 6Hauser RA,Rascol O,Korczyn AD,et al.Ten-year follow-up of Parkinson' s disease patients randomized to initial therapy with ropinirole or levodopa.Mov Disord,2007,22:2409-2417.
  • 7Holloway RG,Shoulson I,Fahn S,et al.Pramipexole vs levodopa as initial treatment for Parkinson disease:a 4-year randomized controlled trial.Arch Neurol,2004,61:1044-1053.
  • 8Parkinson Study Group CALM Cohort Investigatiors.Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.Arch Neurol,2009,66:563-570.
  • 9Oertel WH,Wolters E,Sampaio C,et al.Pergolide versus levodopa monotherapy in early Parkinson' s disease patients:the PELMOPET study.Mov Disord,2006,21:343-353.
  • 10Fahn S,Oakes D,Shoulson I,et al.Levodopa and the progression of Parkinson' s disease.N Engl J Med,2004,351:2498 -2508.

共引文献1

同被引文献15

  • 1Marwick TH, Schwaiger M. The future of cardiovascular imaging in the diagnosis and management of heart failure., part 1 : tasks and tools[ J]. Circ Cardiovasc Imaging, 2008, 1 (I) : 58-69.
  • 2Schwaiger M, Kalff V, Rosenspire K, et al. Noninvasive evaluation of sympathetic nervous system in human heart by positron emission tomography [ J ]. Circulation, 1990, 82(2) : 457-464.
  • 3Langer O, Halldin C. PET and SPET tracers for mapping the cardi- ac nervous system[ J ]. Eur J Nucl Med Mol Imaging, 2002, 29 (3) : 416-434.
  • 4Eisenhofer G. The role of neuronal and extraneuronal plasma mem- brane transporters in the inactivation of peripheral catecholamines [J]. Phamlacol Ther, 2001, 91( 1): 35-62.
  • 5何玉林.王雪梅.碳-11标记的N-甲基多巴胺及其制备方法:中国,201110047681[P].2012—04-11.
  • 6Ilias I, Chen CC, Carrasquillo JA, et al. Comparison of 6-1SF-flu- orodopamine PET with 123 I-metaiodobenzylguanidine and 111 in-pen- tetreotide scintigraphy in localization of nonmetastatic and metastat- ic pheochromocytoma[ J]. J Nucl Med, 2008, 49 ( 101 : 1613- 1619.
  • 7Timmers HI, Chen CC, Carrasquillo JA, et at. Comparison of )SF- fluoro-L-DOPA, lSF-fluoro-deoxyglucose, and lSF-fluorodopamine PET and 1231-M1BG scintigraphy in the localization of pheochrumo- cytoma and paraganglioma[ J]. J Clin Endocrinul Metab, 2009, 94 ( 121 : 4757-4767.
  • 8Lee MR. The history of Ephedra (nm-huang) [ J ]. J R Coil Physicians Fxlinb, 2011, 41 ( 1 ) : 78-84.
  • 9Eskola O, Grnroos TJ, Naum A, et al. Novel electrophilic synthe- sis of 6-[ Is F] fluorodopamine and comprehensive biological evalua- tion[J]. Eur J Nucl Med Mol Imaging, 2012, 39(5) : 800-810.
  • 10Del Rosario RB, Jung YW, Caraher J, et at. Synthesis and prelim- inary evaluation of [lIC ]-(-)-phenylephrine as a functional heart neuronal PET agent [ J ]. Nucl Med Biol, 1996, 23 ( 5 ) : 611-616.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部